The strength of our science lies in our people.
About Us
Inner Space Research is a psychiatry-focused clinical research center in Orem, Utah, led by experienced clinicians and investigators dedicated to advancing innovative mental health treatments.
With decades of combined experience and leadership across hundreds of clinical trials, including research on ketamine and emerging psychedelic-assisted therapies, our team works at the intersection of rigorous science and compassionate care. Our purpose is to expand safe, evidence-based treatment options and contribute to research that is shaping the future of mental health.
Dr. Steve Thayer
Ph.D.
CEO and Co-founder
-
Dr. Steve Thayer, Ph.D. is a clinical psychologist who specializes in psychedelic-assisted therapy practice, training, and research. He began his career in the U.S. Air Force where he led mental health care teams, provided therapeutic and assessment services, and counseled military leadership about community mental health concerns. As an adjunct professor, Dr. Thayer has taught graduate and undergraduate courses in counseling skills, clinical psychology, and personality theory. He has served as the lead therapist on several psychedelic medicine clinical trials and currently consults for Compass Pathways as a mentor to the therapists working on their phase 3 trial of psilocybin for treatment-resistant depression.
Dr. Thayer is the Lead Instructor for Numinus Wellness's psychedelic-assisted therapy certification program and co-hosts the popular podcast, Psychedelic Therapy Frontiers. Dr. Thayer has a private therapy and coaching practice where he helps people resolve the unconscious blocks keeping them from creating the happiness, freedom, and relationships they crave.
Dr. Thayer is the CEO and Co-founder at Inner Space Research, a psychiatry-focused clinical research site in Orem, Utah.
Dr. Reid Robison
MD, MBA
Chief Medical Officer and Co-founder
-
Dr. Reid Robison, MD, MBA, is a board-certified psychiatrist and clinical researcher with deep expertise in ketamine and psychedelic medicine. He has served as principal investigator on more than 250 CNS clinical trials. Dr. Robison received his first grant to study ketamine in 2010 and, around that time, led the Utah site for a pivotal IV ketamine trial for treatment-resistant depression in collaboration with Janssen.
He has been principal investigator for numerous Phase II–III clinical trials involving Schedule I psychedelic compounds, including psilocybin, LSD, 5-MeO-DMT, and other serotonergic hallucinogens. Dr. Robison is the first author of the September 2025 JAMA Psychiatry paper reporting results from MindMed’s Phase II study of MM120 for generalized anxiety disorder, and a co-author on the Usona Phase II psilocybin study manuscript. He also served as coordinating investigator for the MAPS-sponsored trial of MDMA-assisted psychotherapy for eating disorders.
Dr. Robison previously founded Cedar Clinical Research—one of the top-enrolling Phase II–III psychedelic trial sites—as well as Cedar Psychiatry, a Utah-based mental health clinic network that grew to more than 50,000 patient visits and delivered over 10,000 Spravato and ketamine therapy sessions annually. Additionally, he has served as Medical Director of Center for Change, a leading eating disorder treatment center, since 2018. He is also the co-host of Psychedelic Therapy Frontiers, a widely regarded podcast exploring emerging research, therapeutic models, and best practices in psychedelic medicine. He also serves as adjunct faculty at the University of Utah and is the founder of the nonprofit organizations Polizzi Free Clinic and the Psychedelic Institute.